Cargando…

Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na(+)/K(+)-ATPase

BACKGROUND: Surface-expressed Na(+)/K(+)-ATPase (NaK) has been suggested to function as a non-canonical cardiotonic steroid-binding receptor that activates multiple signaling cascades, especially in cancer cells. By contrast, the current study establishes a clear correlation between the IC(50)in vit...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno Y Banuls, Laetitia, Katz, Adriana, Miklos, Walter, Cimmino, Alessio, Tal, Daniel M, Ainbinder, Elena, Zehl, Martin, Urban, Ernst, Evidente, Antonio, Kopp, Brigitte, Berger, Walter, Feron, Olivier, Karlish, Steven, Kiss, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722118/
https://www.ncbi.nlm.nih.gov/pubmed/23621895
http://dx.doi.org/10.1186/1476-4598-12-33
_version_ 1782278143976931328
author Moreno Y Banuls, Laetitia
Katz, Adriana
Miklos, Walter
Cimmino, Alessio
Tal, Daniel M
Ainbinder, Elena
Zehl, Martin
Urban, Ernst
Evidente, Antonio
Kopp, Brigitte
Berger, Walter
Feron, Olivier
Karlish, Steven
Kiss, Robert
author_facet Moreno Y Banuls, Laetitia
Katz, Adriana
Miklos, Walter
Cimmino, Alessio
Tal, Daniel M
Ainbinder, Elena
Zehl, Martin
Urban, Ernst
Evidente, Antonio
Kopp, Brigitte
Berger, Walter
Feron, Olivier
Karlish, Steven
Kiss, Robert
author_sort Moreno Y Banuls, Laetitia
collection PubMed
description BACKGROUND: Surface-expressed Na(+)/K(+)-ATPase (NaK) has been suggested to function as a non-canonical cardiotonic steroid-binding receptor that activates multiple signaling cascades, especially in cancer cells. By contrast, the current study establishes a clear correlation between the IC(50)in vitro growth inhibitory concentration in human cancer cells and the Ki for the inhibition of activity of purified human α1β1 NaK. METHODS: The in vitro growth inhibitory effects of seven cardiac glycosides including five cardenolides (ouabain, digoxin, digitoxin, gitoxin, uzarigenin-rhamnoside, and their respective aglycone forms) and two bufadienolides (gamabufotalin-rhamnoside and hellebrin, and their respective aglycone forms) were determined by means of the MTT colorimetric assay and hellebrigenin-induced cytotoxic effects were visualized by means of quantitative videomicroscopy. The binding affinity of ten of the 14 compounds under study was determined with respect to human α1β1, α2β1 and α3β1 NaK complexes. Lactate releases and oxygen consumption rates were also determined in cancer cells treated with these various cardiac glycosides. RESULTS: Although cardiotonic steroid aglycones usually display weaker binding affinity and in vitro anticancer activity than the corresponding glycoside, the current study demonstrates that the hellebrin / hellebrigenin pair is at odds with respect to this rule. In addition, while some cardiac steroid glycosides (e.g., digoxin), but not the aglycones, display a higher binding affinity for the α2β1 and α3β1 than for the α1β1 complex, both hellebrin and its aglycone hellebrigenin display ~2-fold higher binding affinity for α1β1 than for the α2β1 and α3β1 complexes. Finally, the current study highlights a common feature for all cardiotonic steroids analyzed here, namely a dramatic reduction in the oxygen consumption rate in cardenolide- and bufadienolide-treated cells, reflecting a direct impact on mitochondrial oxidative phosphorylation. CONCLUSIONS: Altogether, these data show that the binding affinity of the bufadienolides and cardenolides under study is usually higher for the α2β1 and α3β1 than for the α1β1 NaK complex, excepted for hellebrin and its aglycone form, hellebrigenin, with hellebrigenin being as potent as hellebrin in inhibiting in vitro cancer cell growth.
format Online
Article
Text
id pubmed-3722118
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37221182013-07-25 Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na(+)/K(+)-ATPase Moreno Y Banuls, Laetitia Katz, Adriana Miklos, Walter Cimmino, Alessio Tal, Daniel M Ainbinder, Elena Zehl, Martin Urban, Ernst Evidente, Antonio Kopp, Brigitte Berger, Walter Feron, Olivier Karlish, Steven Kiss, Robert Mol Cancer Research BACKGROUND: Surface-expressed Na(+)/K(+)-ATPase (NaK) has been suggested to function as a non-canonical cardiotonic steroid-binding receptor that activates multiple signaling cascades, especially in cancer cells. By contrast, the current study establishes a clear correlation between the IC(50)in vitro growth inhibitory concentration in human cancer cells and the Ki for the inhibition of activity of purified human α1β1 NaK. METHODS: The in vitro growth inhibitory effects of seven cardiac glycosides including five cardenolides (ouabain, digoxin, digitoxin, gitoxin, uzarigenin-rhamnoside, and their respective aglycone forms) and two bufadienolides (gamabufotalin-rhamnoside and hellebrin, and their respective aglycone forms) were determined by means of the MTT colorimetric assay and hellebrigenin-induced cytotoxic effects were visualized by means of quantitative videomicroscopy. The binding affinity of ten of the 14 compounds under study was determined with respect to human α1β1, α2β1 and α3β1 NaK complexes. Lactate releases and oxygen consumption rates were also determined in cancer cells treated with these various cardiac glycosides. RESULTS: Although cardiotonic steroid aglycones usually display weaker binding affinity and in vitro anticancer activity than the corresponding glycoside, the current study demonstrates that the hellebrin / hellebrigenin pair is at odds with respect to this rule. In addition, while some cardiac steroid glycosides (e.g., digoxin), but not the aglycones, display a higher binding affinity for the α2β1 and α3β1 than for the α1β1 complex, both hellebrin and its aglycone hellebrigenin display ~2-fold higher binding affinity for α1β1 than for the α2β1 and α3β1 complexes. Finally, the current study highlights a common feature for all cardiotonic steroids analyzed here, namely a dramatic reduction in the oxygen consumption rate in cardenolide- and bufadienolide-treated cells, reflecting a direct impact on mitochondrial oxidative phosphorylation. CONCLUSIONS: Altogether, these data show that the binding affinity of the bufadienolides and cardenolides under study is usually higher for the α2β1 and α3β1 than for the α1β1 NaK complex, excepted for hellebrin and its aglycone form, hellebrigenin, with hellebrigenin being as potent as hellebrin in inhibiting in vitro cancer cell growth. BioMed Central 2013-04-26 /pmc/articles/PMC3722118/ /pubmed/23621895 http://dx.doi.org/10.1186/1476-4598-12-33 Text en Copyright © 2013 Moreno Y Banuls et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Moreno Y Banuls, Laetitia
Katz, Adriana
Miklos, Walter
Cimmino, Alessio
Tal, Daniel M
Ainbinder, Elena
Zehl, Martin
Urban, Ernst
Evidente, Antonio
Kopp, Brigitte
Berger, Walter
Feron, Olivier
Karlish, Steven
Kiss, Robert
Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na(+)/K(+)-ATPase
title Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na(+)/K(+)-ATPase
title_full Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na(+)/K(+)-ATPase
title_fullStr Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na(+)/K(+)-ATPase
title_full_unstemmed Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na(+)/K(+)-ATPase
title_short Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na(+)/K(+)-ATPase
title_sort hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the na(+)/k(+)-atpase
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722118/
https://www.ncbi.nlm.nih.gov/pubmed/23621895
http://dx.doi.org/10.1186/1476-4598-12-33
work_keys_str_mv AT morenoybanulslaetitia hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT katzadriana hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT mikloswalter hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT cimminoalessio hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT taldanielm hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT ainbinderelena hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT zehlmartin hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT urbanernst hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT evidenteantonio hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT koppbrigitte hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT bergerwalter hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT feronolivier hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT karlishsteven hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase
AT kissrobert hellebrinanditsaglyconeformhellebrigenindisplaysimilarinvitrogrowthinhibitoryeffectsincancercellsandbindingprofilestothealphasubunitsofthenakatpase